Reference 39 Human Papillomavirus Triage Test for Women with Possible or Definite Low-Grade Squamous Intraepithelial Lesions
Human Papillomavirus Triage Test for Women with Possible or Definite Low-Grade squamous intraepithelial lesions
Reference No. | 39 |
| Reference Name | Human Papillomavirus Triage Test for Women with Possible or Definite Low-Grade Squamous Intraepithelial Lesions |
| Advisory Panel | Professor Brendon Kearney (Chair) (MSAC Member until 31/12/2008) Dr Ewa Piejko (Deputy Chair) (MSAC Member until 30/09/2008) Dr Marion Saville (Australian Society of Cytology nominee) Dr Huw Llewellyn (Royal College of Pathologists of Australasia nominee) Dr Louise Farrell (Royal Australian and New Zealand College of Obstetricians and Gynaecologists nominee) Assoc Professor Danielle Mazza (Royal Australian College of General Practitioners nominee) Mr Alan Keith (Director Screening Section – Department of Health and Ageing – Observer status) Ms Diane Walsh (Consumers’ Health Forum nominee) |
| Date Received by MSAC Secretariat | 28 September 2006 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | MSAC considered this assessment on 20 March 2009. The Minister noted MSAC's advice 20 August 2009. |
| Stage 4 - Decision | MSAC finds that human papilloma virus (HPV) triage for Pap smear, compared with repeat recall cytology at one year, is safe and is effective but is not cost effective in the Australian setting at the current price of HPV testing. MSAC does not support public funding for HPV triage testing in cervical cancer. |
| Stage 5 - Implementation |  |
Page currency, Latest update: 07 October, 2009
